

USING A JAK-STAT INHIBITOR IN MODERATE-SEVERE ULCERATIVE COLITIS ASSOCIATED WITH HIDRADENITIS SUPPURATIVA: PROBABLY NOT A FAUX PAS!

Marina Cipullo

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A case report describes marked improvement of both ulcerative colitis and concurrent hidradenitis suppurativa in a 26-year-old woman treated with tofacitinib after adalimumab failure.

KEY POINTS

- The patient had pancolitis (UC E3, Mayo ESS 2) with steroid dependence and primary failure to adalimumab, plus hidradenitis suppurativa affecting axillary folds, inguinal folds, and intermammary groove that failed topical dermatologic treatment.
- Tofacitinib 20 mg daily was introduced in March 2022 for 16 weeks (extended induction), achieving UC clinical and biochemical remission and marked amelioration of hidradenitis suppurativa.
- The patient continues maintenance therapy with tofacitinib 10 mg daily.
- The authors note there is no prior evidence on the efficacy of tofacitinib in hidradenitis suppurativa, though it has been introduced into European guidelines for moderate-severe ulcerative colitis.
- This case may interest gastroenterologists and dermatologists managing patients with concurrent inflammatory bowel disease and hidradenitis suppurativa.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/1f1d5d02-743c-11ee-99a1-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.